Best Immunotherapy Companies in Netherlands
The 46 best Immunotherapy companies in Netherlands in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Crucell.
- ResearchAndMarkets.com
- The Business Research Company
Our analysis of 50 Immunotherapy companies
$8.8b in tracked funding; 69% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Immunotherapy companies in Netherlands
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Crucell Crucell researches and develops products and markets vaccines, proteins and antibodies for the treatment of… | $443M | 127 mo ago | 1,300 | — | — | — | — |
| 2 | NewAmsterdam Pharma Developer of transformative therapeutic solutions for cardio-metabolic diseases | $196M | 67 mo ago | 17 | John Kastelein Founder & CSO | DrupalApple iCloud MailPHP+26 | 124 patents CETP inhibitor drug development and formulation, especially obicetrapib for cardiovascular and dementia therapy | 2 awards |
| 3 | VectoryTx Developer of therapeutics for neurodegenerative and muscular disorder | $176M | 33 mo ago | 78 | Sander Van Deventer Chief Executive Officer | Cart FunctionalitySquarespace CommerceSquarespace+16 | — | 2 job openings |
| 4 | Merus Developer of antibody-based drugs for cancer treatment | $156M | 91 mo ago | 221 | — | WordPressApple iCloud MailMicrosoft 365+22 | 1,027 patents Bispecific antibody therapeutics targeting cancer and immune checkpoints for oncology applications. | — |
| 5 | LAVA therapeutics Developer of novel gamma delta T-cell engagers to treat cancer | $102M | 71 mo ago | 15 | Erik van den Berg Co-Founder | DrupalApple iCloud MailMicrosoft 365+20 | 134 patents Multispecific antibody therapeutics linking gamma‑delta TCRs to tumor antigens | — |
| 6 | Xenikos Developer of toxin-loaded antibodies for T-cell mediated diseases | $82M | 46 mo ago | 17 | — | — | 6 patents Targeted immunotoxin therapeutics for cancer treatment | — |
| 7 | Tagworks Pharmaceuticals Developer of antibody-drug-conjugates for cancer treatment | $65M | 37 mo ago | 13 | Zach Taylor Co-Founder | WordPressMySQLPHP+22 | 144 patents Bioorthogonal click chemistry reagents for targeted drug/protein delivery and release | — |
| 8 | Avidicure Developer of immunotherapies for cancer therapeutics | $50M | 15 mo ago | — | Govert Schouten Co-Founder | WordPressMySQLPHP+10 | 22 patents Multispecific antibody‑cytokine fusion proteins for targeted cancer immunotherapy | — |
| 9 | TargED Developer of biological drugs for the treatment of thrombosis | $46M | 8 mo ago | 17 | Steven Maat Co-Founder | WordPressMySQLPHP+15 | — | 2 job openings |
| 10 | ISA Pharmaceuticals Developer of therapeutic vaccines for cancer and infectious diseases | $41M | 61 mo ago | 44 | — | — | 90 patents Peptide-based therapeutic cancer vaccines and immunogenic formulations combined with PD‑1 inhibitors | — |
| 11 | Citryll Targeting neutrophil extracellular traps for autoimmune diseases | $38M | 20 mo ago | 19 | Eduardo Bravo Chief Executive Officer | WordPressMySQLPHP+20 | 56 patents Anti‑citrullinated histone antibodies for rheumatoid arthritis diagnostics and therapeutics | — |
| 12 | Bilthoven Biologicals Large scale vaccines manufacturer for infectious diseases, such as polio and tetanus | $29M | 37 mo ago | 371 | Jan-Eric Zandbergen CEO | WordPressMySQLPHP+15 | — | 2 partnerships |
| 13 | Mucosis Mucosal vaccines for the prevention and treatment of infectious diseases (specifically against respiratory… | $15M | 126 mo ago | 16 | — | — | 45 patents Thermostable vaccine antigens and adjuvant formulations for RSV and recombinant proteins | — |
| 14 | Synerkine Pharma Developer of therapeutics to treat osteoarthritis and chronic pain | $13M | 34 mo ago | 2 | Erik Hack Co-Founder | — | 26 patents Engineered cytokine fusion proteins for targeted immunotherapy and anti‑inflammatory applications | — |
| 15 | ORCA Therapeutics Provider of virus mediated immunotherapy for cancer | $9M | 123 mo ago | 4 | — | — | 9 patents Patents concentrated in chemistry & materials | — |
| 16 | Gadeta T Cell based cancer therapies based on gamma delta (γδ) T cell receptors | $8M | 68 mo ago | 31 | — | — | 61 patents Engineered gamma‑delta T‑cell receptors and cell therapies for cancer and infection | — |
| 17 | Encare Biotech Specialty company developing a new therapeutic antibody for the prevention of heart failure after acute… | $7M | 140 mo ago | — | MARK BOER CEO | — | 13 patents Therapeutic antibodies targeting fibronectin-EDA for anti‑fibrotic and inflammatory treatment | — |
| 18 | Glycostem Therapeutics Developer of allogeneic cellular immunotherapy for leukemia, lymphoma and solid tumors | $6M | 83 mo ago | 38 | — | DrupalApple iCloud MailPHP+12 | 30 patents Engineered NK cell immunotherapies and manufacturing methods for cancer treatment | — |
| 19 | FF Pharma MAbs for inflammatory diseases like primary biliary cirrhosis and Crohn’s disease | $5M | 162 mo ago | — | Mark de Boer CEO | — | 151 patents Therapeutic recombinant alkaline phosphatase enzymes for kidney injury and sepsis treatment | — |
| 20 | Pan Cancer T Provider of TCR T-cell therapeutics for the treatment of cancer | $5M | 8 mo ago | 8 | Reno Debets Founder | WordPressMySQLPHP+13 | — | — |
| 21 | Apo-T Dutch, private, biopharma company developing antibody-drug conjugates and apoptosis-inducers for cancer… | $3M | 148 mo ago | — | dr Willemsen Founder | — | 67 patents Bispecific immunotherapeutic agents directing immune cells to tumor antigens | — |
| 22 | Allero Therapeutics Developer of immunotherapies for allergy and autoimmune disease | $3M | 47 mo ago | 5 | Kees Leenhouts Co-Founder / Chief Technology Officer & Chief Operations Officer | — | 3 patents mRNA and antigen-specific immunotherapies for treating immune disorders and viral‑induced inflammation | — |
| 23 | Amphera Developing dendritic cell immunotherapies for treating malignant mesothelioma and other cancers | $538K | 127 mo ago | 4 | Rob Meijer CEO | — | 27 patents Cancer immunotherapy vaccines using dendritic cells loaded with tumor-derived lysates | — |
| 24 | CiMaas Developer of immunotherapeutics for cancer treatment | $313K | 79 mo ago | 9 | Wilfred V Germeraad Co-Founder & COO | — | 7 patents Manufacturing and preparation of mitotically suppressed and mature dendritic cells for cell therapies | — |
| 25 | Treeway Co-developing immunotherapy drugs for Amyotrophic lateral sclerosis (ALS) | $111K | 135 mo ago | — | Bernard Muller Founder & Solutionist | — | — | — |
| 26 | Frame Therapeutics Developer of immunotherapies for cancer treatment | $111K | 78 mo ago | 13 | Bob Lowenberg Co-Founder | — | — | — |
Top 12 Immunotherapy companies in Netherlands
#1
Series A · Utrecht, Utrecht · founded 2020 · 17 employees$45.8Mraised▾
Developer of biological drugs for the treatment of thrombosis. The company offers its FDA-approved biological drugs and TargED Targeted Enzyme Delivery system which is a small antibody that can target the specific sites of thrombosis and enable the blood flow to reduce the risk for organ failure is reduced. The company target Thrombotic thrombocytopenic purpura (TTP) and Acute Ischemic Stroke (AIS) and the lead compound Microlyse is a thrombolytic fusion protein that consisting two subunits i.e a nanobody domain targeting Von Willebrand Factor (VWF) which helps in wound healing also and the protease domain of the plasminogen activator urokinase. It targets the protease domain towards VWF, to active degradation of both VWF and fibrin.
- Dec 2025Series A$25.2M
- Jul 2025Grant (prize money)$2.9M
- Jul 2025Series A$11.8M
- Feb 2022Series A$44.2M
#2
Series A · Rotterdam, South Holland · founded 2020 · 8 employees$4.6Mraised▾
Provider of TCR T-cell therapeutics for the treatment of cancer. The company uses the adoptive T cell therapies for treating pan-cancer. The company pipeline product includes MAGE-C2/HLA-A2 TCR and epigenetic drugs which can be used in the treatment of melanoma and head-and-neck carcinoma. The company also offers Pan-Cancer T’s platforms which include a dose-escalation of TCR T cells.
- Dec 2025Series A$5.8M
- Dec 2025Conventional Debt$5.8M
- Jul 2024Seed$4.6M
- Oct 2021Seed—
#3
Seed · Amsterdam, North Holland · founded 2022$50Mraised▾
Developer of immunotherapies for cancer therapeutics. It offers AVC-Boosters supercharged antibodies that boost the number and function of NK cells at the tumor, cause activation of the full immune system and provide broad TME-resistant anti-tumor responses.
- Apr 2025Seed$50M
#4
Series B · Amsterdam, North Holland · founded 2015 · 19 employees$37.7Mraised▾
Citryll is a US-based biopharma developing antibody therapeutics to target neutrophil extracellular traps for autoimmune diseases like Rheumatoid Arthritis (RA), Colitis and others. The therapeutics work by extinguishing the source of auto-antigens and neutrophil extracellular trap (NET) derived toxic molecules instead of broadly targeting inflammation. The company is a spin-out from ModiQuest. Citryll has a proprietary toolbox to study NET biology and protein citrullination and their role in human pathologies. Citryll’s lead programme tACPA, targets the formation of neutrophil extracellular traps, called NETs. These drugs work by interfering with the formation, function, and clearance of NETs downstream of the protein citrullination pathway catalyzed by peptidyl-arginine deiminase (PAD) enzymes.
- Dec 2024Series B$89.8M
- Jul 2020Series B$20.8M
- Jul 2020Grant (prize money)—
- Jul 2019Series A$16.9M
#5
Series A · Amsterdam, North Holland · founded 2020 · 78 employees$175.6Mraised▾
Developer of therapeutics for neurodegenerative and muscular disorders. The products contain next-generation viral vectors that target specific cell types and subcellular compartments while evading the host immune response. The company is developing therapeutics based on an AAV gene therapy platform, antibody, and RNA-targeted degradation technologies.
- Nov 2023Series A$138M
- Jun 2021Seed$37.6M
#6
Series A · Nijmegen, Gelderland · founded 2011 · 13 employees$65Mraised▾
Developer of antibody-drug-conjugates for cancer treatment. It offers a lead product TGW101 that targets TAG72, a non-internalizing clinically validated pan-carcinoma target, present in several solid tumors. It also offersolid-tumor-targeted ADCs as well as radiopharmaceuticals including a HER2-targeted radioimmunotherapeutic.
- Jun 2023Series A$65M
- Mar 2023Grant (prize money)$477.5K
- Mar 2018Grant (prize money)$313.3K
- Jan 2016Grant (prize money)$1.7M
#7
Series C · Nijmegen, Gelderland · founded 2009 · 17 employees$82Mraised▾
Developer of toxin-loaded antibodies for T-cell mediated diseases. Based on the action of conjugated antibodies, it has developed its lead candidate T-Guard, a combination of two toxin-loaded anti-T-cell antibodies that can reset the body's immune system in T-cell mediated diseases, such as Graft-versus-host disease (GVHD).
- Oct 2022Grant (prize money)$2.5M
- Sep 2021Series C$47.4M
- May 2018Series B$30M
- Jun 2012Grant (prize money)$2.4M
#8
Acquired · Leiden, South Holland · founded 1993 · 1300 employees$443Mraised▾
Crucell focused on research development, production and marketing of vaccines, proteins and antibodies that prevent and/or treat infectious diseases. Crucell’s core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and aluminum-free hepatitis A vaccine.
- Jan 2016Grant (prize money)$92.1K
- Sep 2009PE$443M
#9
Acquired · Bilthoven, Utrecht · founded 2012 · 371 employees$28.6Mraised▾
Bilthoven Biologicals produces large scale vaccines for infectious diseases, such as polio and tetanus. It was acquired by Poonawalla Group (Serum Institute, Indian vaccine manufacturer) in Jul.2012. The company manufacturers more than 20M vaccine units each year and sells in more than 25 countries.
- Jun 2023Grant (prize money)$28.6M
#10
Public · Naarden, North Holland · founded 2019 · 17 employees$196Mraised▾
Developer of transformative therapeutic solutions for cardio-metabolic diseases. It has developed obicetrapib that is a small molecule, oral cholesterol ester transfer protein inhibitor. It is a protein inhibitor that targets Apolipoprotein B (ApoB) and low-density lipoprotein cholesterol (LDL-c) in the body. It is developing transformative therapies including obicetrapib for cardio-renal diseases.
- Jan 2021Series A$196M
#11
Series A · Naarden, North Holland · founded 2018 · 2 employees$13.3Mraised▾
Developer of therapeutics to treat osteoarthritis and chronic pain. The company is focusing on the development of novel fusion proteins that combine the immunoregulatory activity of different cytokines which has therapeutic applications for osteoarthritis, chronic pain, and Chemotherapy-Induced Peripheral Neuropathy (CIPN).
- Oct 2023Series A$5.6M
- Oct 2023Conventional Debt—
- Dec 2021Series A$3.9M
- Mar 2019Series A$3.7M
#12
Acquired · Utrecht, Utrecht · founded 2003 · 221 employees$156.2Mraised▾
Developer of antibody-based drugs for cancer treatment. The company develops products using bispecific antibody engineering and advanced screening technologies that engage the power of the immune system to kill cancer cells. Its products include Zenocutuzomab, Petosemtamab, and MCLA-145 for lung, pancreatic and other cancers.
- Dec 2018Post IPO$15M
- Feb 2018Post IPO$55.8M
- Jan 2017Post IPO$80M
- Nov 2016Grant (prize money)—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Immunotherapy coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Immunology & Immunotherapy is moving in the Netherlands
A read on the academic research around Immunology & Immunotherapy — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 724 Netherlands-affiliated papers.
- Leiden University Medical Center104
- Amsterdam University Medical Centers98
- Radboud University Medical Center76
- Erasmus MC74
- Radboud University Nijmegen73
- Immune system3→67
- Tumor microenvironment1→19
- Immune checkpoint1→17
- T cell2→16
- Cancer immunotherapy1→15
- Immune system12→118
- Oncology4→44
- Internal medicine4→41
- Cancer research7→36
- Cancer11→37
- Immune system7→48
- Clinical trial2→14
- Cancer4→14
- Internal medicine2→11
- Oncology2→9
Where immunology is researched across Netherlands
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.